Certara’s combined PBPK/QSP model predicts safety and efficacy biomarker outcomes in Alzheimer’s Disease, as demonstrated in recent lecanemab work with Eisai ホワイトペーパー
Immunogenicity Prediction and Dose Optimization using Clinically-Validated In Silico Modeling and Simulation ホワイトペーパー